A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.

ABSTRACT:

Purpose

Selinexor is an oral selective inhibitor of exportin-1 (XPO1) with efficacy in various solid and hematologic tumors. We assessed intratumoral penetration, safety, and efficacy of selinexor monotherapy for recurrent glioblastoma.

Patients and methods

Seventy-six adults with Karnofsky Performance Status ≥ 60 were enrolled. Patients undergoing cytoreductive surgery received up to three selinexor doses (twice weekly) preoperatively (Arm A; n = 8 patients). Patients not undergoing surgery received 50 mg/m² (Arm B, n = 24), or 60 mg (Arm C, n = 14) twice weekly, or 80 mg once weekly (Arm D; n = 30). Primary endpoint was 6-month progression-free survival rate (PFS6).

Results

Median selinexor concentrations in resected tumors fro

SUBMITTER: Lassman AB 

PROVIDER: S-EPMC8810630 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature